Philips Unveils IntraSight Plus With FDA 510(k) Clearance And CE Marking, Combining IVUS, Physiology And Angiography On Single Screen For Coronary Interventions - Koninklijke Philips (NYSE:PHG)
Published on March 25, 2026.
The article discusses the launch of the IntraSight Plus, which combines IVUS, Physiology, and Angiography on a single screen for Coronary Interventions. The company's announcement of the new product is seen as an attempt to combat the trend of "anticantic" and "anticomise".
Related Articles
These Sleep Issues Could Be Early Warning Signs Of Dementia
Chronic sleep disturbances may be early warning signs of dementia, affecting brain function, memory loss, and circadian rhythm issues.
Mortgage demand drops more than 10% as rates hit the highest level since October
Mortgage demand plummeted 10.5% as 30-year fixed rate rates hit their highest since October, driven by rising inflation and rising oil prices.
FDA removes menopause hormone therapy warning after 20 years, opening new options for women
The FDA is removing safety labels from six hormone replacement products, easing the risk of menopause symptoms, but still encouraging appropriate management despite its initial concerns.